Platform therapeutics will revolutionize drug development
The guest argued that transitioning from single-asset drug development to platform therapeutics—building a common technological infrastructure for multiple medicines—will radically de-risk and accelerate future drug pipelines.
The argument
Traditional biotech treats each drug as a bespoke project, starting from square one each time. By contrast, a platform approach (such as Moderna's mRNA platform) allows rapid deployment of new treatments because the underlying delivery and manufacturing infrastructure are already established and de-risked.
The thesis, stress-tested
✓ What validates it
- ✓Regulatory approval of multi-drug platforms
- ✓Successful clinical readouts of secondary assets built on an existing platform
▸ Risks discussed
- ▸High upfront investment costs
- ▸Binary clinical trial outcomes
- ▸Regulatory hurdles for novel platforms
Hear it yourself
"You have Jamie, who is CEO of Alden Scientific, a l d e n, and then you have Phil, who is CEO of Holobiome, h o l o b I o m e. And both of them ended up winning ARPA h grants for the research and work that they're doing. And ARPA h, for people who don't know, is modeled on the defense agency DARPA, which is incredible in its own right. And ARPA h does not operate its own laboratories. Instead, it funds or empowers visionary teams to take bold, seemingly impossible challenges in human health. And they do that by pulling from private industry, universities, and elsewhere. So this is for the high risk, high reward experiments and projects in biomedical and health breakthroughs."
03:45
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE